(Q50588287)

16 March 2018

title

Efficacy of combined interferon and ribavirin for treatment of hepatitis C. (English)

1 reference

16 March 2018

1 reference

J L Brown

1

1 reference

16 March 2018

language of work or name

English

0 references

publication date

1 January 1998

1 reference

16 March 2018

published in

The Lancet

1 reference

16 March 2018

volume

351

1 reference

16 March 2018

page(s)

78-79

1 reference

16 March 2018

issue

9096

1 reference

16 March 2018

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2978157-5

7 January 2021

Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2978157-5

7 January 2021

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2978157-5

7 January 2021

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2978157-5

7 January 2021

Hepatitis C infection from anti-D immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2978157-5

7 January 2021

Long-term persistence of hepatitis C virus antibodies in a single source outbreak

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2978157-5

7 January 2021

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2978157-5

7 January 2021

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2978157-5

7 January 2021

Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2978157-5

7 January 2021

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2978157-5

7 January 2021

Ribavirin treatment for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2978157-5

7 January 2021

Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2978157-5

7 January 2021

Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2978157-5

7 January 2021

Viral dynamics in human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2978157-5

7 January 2021

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2978157-5

7 January 2021

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2978157-5

7 January 2021

Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2978157-5

7 January 2021

10.1016/S0140-6736(05)78157-5

Identifiers

DOI

1 reference

16 March 2018

PubMed ID

9439486

1 reference

16 March 2018